Famed Value Investor Bill Miller Says Facebook Stock has Gotten Too Cheap: ‘This Too will Pass’ (CNBC)
Famed investor Bill Miller is still a believer in Facebook. “This too will pass,” he said in an email to CNBC’s Scott Wapner. The stock’s valuation is “too cheap.” The investor did not comment on whether he is buying more shares in the social media giant. He confirmed his firm still owns Facebook shares. Facebook’s stock has declined 9 percent this week through Tuesday after the weekend media reports on the company’s data scandal. Nearly $50 billion of market value has been wiped off its shares since Friday. Shares of Facebook rose 2.5 percent Wednesday.
John Paulson Returns Money From Gold, Special Situations Funds (Bloomberg)
John Paulson’s gold and special situations hedge funds are among those returning client capital as the firm narrows its focus after shedding almost $30 billion in assets. One of the firm’s Credit Opportunities funds is also forcing clients to redeem, according to people familiar with the matter. A second credit fund will remain open, and investors can move their money into that offering. Investors can also switch into the merger-focused Pure Spread fund and the European Event Equities fund. A representative for the firm declined to comment.
Maxx-Studio/Shutterstock.com
Warren Buffett’s Vision for NetJets is Now the Company Mantra, New Europe CEO Says (CNBC)
The new CEO of NetJets Europe said Tuesday that he plans to follow a very clear mantra from ultimate owner Warren Buffett. NetJets offers fractional jet ownership and pay-by-the-hour travel to executives who either cannot afford to or don’t see the value in buying a private jet outright. After three years as a customer, Buffett’s Berkshire Hathaway firm bought NetJets in 1998. In 2012, Buffett doubled down with an $18 billion investment allowing the company to buy new jets.
Insider Buying: Amicus Therapeutics, Inc. (NASDAQ:FOLD) Major Shareholder Acquires 100,000 Shares of Stock (TheLincolnianOnline.com)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) major shareholder Life Sciences Maste Perceptive purchased 100,000 shares of Amicus Therapeutics stock in a transaction dated Thursday, March 1st. The shares were acquired at an average cost of $13.69 per share, for a total transaction of $1,369,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission.
Insider Selling: Workday Inc (WDAY) CEO Sells 75,000 Shares of Stock (StockNewsTimes.com)
Workday Inc (NASDAQ:WDAY) CEO Aneel Bhusri sold 75,000 shares of the firm’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $127.23, for a total value of $9,542,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission.
